Cancer immunotherapy has progressed, extending survival for advanced patients. While clinical outcomes generate interest, benefits remain limited, necessitating further research for clarity.
Jingjing Zhu and her lab’s research revolves around cancer immunotherapy, delving into the intricacies of the tumor microenvironment and its profound impact on treatment outcomes. Through the application of cutting-edge techniques and diverse model systems, the team systematically explores immunosuppressive mechanisms, including T cell dysfunction and the influential effects of the tumor microenvironment. These insights serve as the foundation for pioneering novel immunotherapeutic strategies and identifying promising drug targets. The lab's accomplishments span significant breakthroughs, including the identification of critical pathways such as tumor-infiltrating T cell apoptosis initiated by Fas ligand. Notably, the lab's work has spotlighted the adrenergic receptor alpha-2 as a novel and potent target for anti-cancer therapy, an achievement underscored by a prominent publication in the journal Nature. Additionally, the lab is actively involved in a sustained endeavor to uncover genes pivotal to T cell dysfunction. The pursuit of precision in treatment is evident in the lab's innovative methodologies, exemplified by the development of targeted drug delivery strategies—such as the deployment of anti-PD L1 nanobodies via specialized anti-tumor CD8 T cells, yielding notable success in controlling tumors as demonstrated in a murine model. With unwavering confidence in the potential of anti-cancer immunotherapy, Jingjing and her team remains dedicated to unearthing novel mechanisms of immunomodulation and fostering collaborative ventures within the industrial landscape to drive transformative progress in the field.